{
    "organizations": [],
    "uuid": "067da7f5cf0beec7e2a8cb84f04fc2243b851f4b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-biocryst-reports-q4-loss-per-share/brief-biocryst-reports-q4-loss-per-share-of-0-20-idUSASB0C7PP",
    "ord_in_thread": 0,
    "title": "BRIEF-Biocryst Reports Q4 Loss Per Share of $0.20",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - Biocryst Pharmaceuticals Inc:\n* BIOCRYST REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS\n* Q4 LOSS PER SHARE $0.20 * Q4 REVENUE $3.9 MILLION VERSUS $9.0 MILLION * CASH, CASH EQUIVALENTS & INVESTMENTS TOTALED $159.0 MILLION AT DEC 31, 2017, REFLECTS INCREASE FROM $65.1 MILLION AT DEC 31, 2016\n* EXPECTS ITS 2018 NET OPERATING CASH USE TO BE IN RANGE OF $67 TO $90 MILLION\n* SEES 2018 OPERATING EXPENSES TO BE IN RANGE OF $85 TO $110 MILLION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-27T21:44:00.000+02:00",
    "crawled": "2018-02-28T12:47:50.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "biocryst",
        "pharmaceutical",
        "inc",
        "biocryst",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "q4",
        "loss",
        "per",
        "share",
        "q4",
        "revenue",
        "million",
        "versus",
        "million",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "totaled",
        "million",
        "dec",
        "reflects",
        "increase",
        "million",
        "dec",
        "expects",
        "net",
        "operating",
        "cash",
        "use",
        "range",
        "million",
        "see",
        "operating",
        "expense",
        "range",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}